ABT - Abbott Laboratories
NYSE
->
Healthcare
->
Medical Devices
North Chicago,
United States
Type: Equity
ABT price evolution
ABT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6987 | $6284 | $7279 | |
| Short term investments | $232 | $367 | ||
| Net receivables | $6854 | $6605 | $6565 | |
| Inventory | $6814 | $6827 | $6570 | |
| Total current assets | $23119 | $22376 | $22670 | |
| Long term investments | $877 | $818 | $799 | |
| Property, plant & equipment | $10233 | $10107 | $10154 | |
| Goodwill & intangible assets | $31135 | $31679 | $32494 | |
| Total noncurrent assets | $49898 | $50091 | $50544 | |
| Total investments | $1109 | $1185 | $799 | |
| Total assets | $73017 | $72467 | $73214 | |
| Current liabilities | ||||
| Accounts payable | $4125 | $4178 | $4295 | |
| Deferred revenue | ||||
| Short long term debt | $1615 | $2010 | $1080 | |
| Total current liabilities | $13760 | $14021 | $13841 | |
| Long term debt | $13139 | $12576 | $13599 | |
| Total noncurrent liabilities | $19697 | $19403 | $20546 | |
| Total debt | $14754 | $14586 | $14679 | |
| Total liabilities | $33457 | $33424 | $34387 | |
| Shareholders' equity | ||||
| Retained earnings | $38354 | $38011 | $37554 | |
| Other shareholder equity | -$8135 | -$8166 | -$7839 | |
| Total shareholder equity | $39560 | $39043 | $38827 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7279 | $10170 | $10249 | $7148 |
| Short term investments | $310 | |||
| Net receivables | $6565 | $6218 | $6487 | $6414 |
| Inventory | $6570 | $6173 | $5157 | $5012 |
| Total current assets | $22670 | $25224 | $24239 | $20441 |
| Long term investments | $799 | $766 | $816 | $821 |
| Property, plant & equipment | $10154 | $10278 | $8959 | $9029 |
| Goodwill & intangible assets | $32494 | $33253 | $35970 | $38528 |
| Total noncurrent assets | $50544 | $49214 | $50957 | $52107 |
| Total investments | $799 | $766 | $816 | $821 |
| Total assets | $73214 | $74438 | $75196 | $72548 |
| Current liabilities | ||||
| Accounts payable | $4295 | $4607 | $4408 | $3946 |
| Deferred revenue | ||||
| Short long term debt | $1080 | $2251 | $754 | $220 |
| Total current liabilities | $13841 | $15489 | $13105 | $11907 |
| Long term debt | $13599 | $14522 | $17296 | $18527 |
| Total noncurrent liabilities | $20546 | $22044 | $26067 | $27638 |
| Total debt | $14679 | $16773 | $18050 | $18747 |
| Total liabilities | $34387 | $37752 | $39172 | $39545 |
| Shareholders' equity | ||||
| Retained earnings | $37554 | $35257 | $31528 | $27627 |
| Other shareholder equity | -$7839 | -$8051 | -$8374 | -$8946 |
| Total shareholder equity | $38827 | $36905 | $36024 | $33003 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10635 | $10377 | $9964 | |
| Cost of revenue | $4603 | |||
| Gross Profit | $5937 | $5774 | $5501 | |
| Operating activities | ||||
| Research & development | $698 | |||
| Selling, general & administrative | $2936 | |||
| Total operating expenses | $4054 | $4105 | $4060 | |
| Operating income | $1669 | |||
| Income from continuing operations | ||||
| EBIT | $1747 | |||
| Income tax expense | $294 | $305 | $211 | |
| Interest expense | -$40 | $140 | -$61 | |
| Net income | ||||
| Net income | $1646 | $1302 | $1225 | |
| Income (for common shares) | $1302 | |||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $40109 | $43653 | $34608 | |
| Cost of revenue | $19142 | $15003 | ||
| Gross Profit | $22134 | $24511 | $19605 | |
| Operating activities | ||||
| Research & development | $2888 | $2420 | ||
| Selling, general & administrative | $11248 | $9696 | ||
| Total operating expenses | $15332 | $16149 | $14248 | |
| Operating income | $8362 | $5357 | ||
| Income from continuing operations | ||||
| EBIT | $8864 | $5538 | ||
| Income tax expense | $941 | $1373 | $497 | |
| Interest expense | -$293 | $558 | $546 | |
| Net income | ||||
| Net income | $5723 | $6933 | $4495 | |
| Income (for common shares) | $6933 | $4495 | ||
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $1302 | $1225 | $1594 | $1436 |
| Operating activities | ||||
| Depreciation | $805 | $805 | $813 | $824 |
| Business acquisitions & disposals | $1 | -$51 | ||
| Stock-based compensation | $141 | $304 | $114 | $117 |
| Total cash flows from operations | $1960 | $1025 | $3038 | $1877 |
| Investing activities | ||||
| Capital expenditures | -$533 | -$398 | -$755 | -$560 |
| Investments | $77 | -$28 | -$71 | -$38 |
| Total cash flows from investing | -$453 | -$425 | -$824 | -$634 |
| Financing activities | ||||
| Dividends paid | -$961 | -$957 | -$888 | -$888 |
| Sale and purchase of stock | $10 | -$92 | -$225 | $54 |
| Net borrowings | $160 | -$127 | -$939 | -$1506 |
| Total cash flows from financing | -$791 | -$1176 | -$2052 | -$2340 |
| Effect of exchange rate | -$13 | -$36 | $25 | -$29 |
| Change in cash and equivalents | $703 | -$612 | $187 | -$1126 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5723 | $6933 | $7071 | $4495 |
| Operating activities | ||||
| Depreciation | $3243 | $3267 | $3538 | $3327 |
| Business acquisitions & disposals | -$837 | $48 | -$53 | $16 |
| Stock-based compensation | $644 | $685 | $640 | $546 |
| Total cash flows from operations | $7261 | $9581 | $10533 | $7901 |
| Investing activities | ||||
| Capital expenditures | -$2202 | -$1777 | -$1885 | -$2177 |
| Investments | -$116 | -$33 | -$96 | -$73 |
| Total cash flows from investing | -$3133 | -$1740 | -$2008 | -$2215 |
| Financing activities | ||||
| Dividends paid | -$3556 | -$3309 | -$3202 | -$2560 |
| Sale and purchase of stock | -$1060 | -$3628 | -$2044 | -$158 |
| Net borrowings | -$2475 | -$699 | -$248 | -$50 |
| Total cash flows from financing | -$7091 | -$7636 | -$5494 | -$2779 |
| Effect of exchange rate | -$23 | -$122 | -$70 | $71 |
| Change in cash and equivalents | -$2986 | $83 | $2961 | $2978 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 4.85% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.89 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |